Pharmaceutical labeling is an ideal use case for AI because it’s a complex process that requires high levels of accuracy.
Inaccurate labeling can result in:
With recent breakthroughs in AI technology, pharmaceutical companies have rushed to explore its potential. But many have not seen the impact they expected.
The problem isn’t the AI. It’s how pharma companies are using AI. Instead of implementing standalone AI tools, companies need to put AI inside enterprise processes where it has the most impact. Let’s discuss what we mean by that.
Most pharmaceutical companies currently implement AI solutions in isolated capacities:
Standalone natural language processing systems for regulatory analysis
Independent translation tools
Disconnected quality control systems
Few have managed to integrate these tools into an end-to-end process. So instead of executing work on its own, AI requires humans to frequently step in and manually act on its outputs. This results in a fragmented process that is prone to an unacceptable level of error.
The right way to deploy AI is in a process. But without the right platform, embedding AI in processes involves complex integration work.
A process platform like Appian simplifies AI integration. Here’s how.
Appian’s low-code development environment treats AI like any other design object—modularizing it so it can be easily configured and added to process models.
For example, Appian offers pretrained AI models called AI skills. The prompt builder AI skill lets users integrate generative AI into any stage of the labeling process. For regulatory submissions, an AI skill can analyze and compare content, extract key data, and improve review accuracy. Just like other design objects in Appian, users can instantly embed AI skills in processes by dragging and dropping them into the Appian Process Modeler.
The Appian Process Modeler integrates AI as a native object in a low-code environment
AI is powered by data. A data fabric connects data across an enterprise in a virtual database. The labeling process involves lots of data stored in different places. Data fabric gives AI access to exactly the data it needs, when it needs it—even if it’s remote.
With Appian’s Private AI, your data remains secure and exclusively yours. Unlike other AI models, your data is never used for AI training or development. Data fabric also provides row-level security, preventing unauthorized access and ensuring compliance with regulatory requirements.
Appian AI capabilities improve the pharmaceutical labeling process. And because Appian takes a private AI approach, all data involved in the process stays secure—your data stays in your control, and we never train our AI models on it.
Appian’s AI capabilities and features include the following.
Appian generative AI can generate label text, expediting the label creation process. AI notifies human experts to validate the text for oversight.
Records chat is an Appian interface component that creates a chatbot for chatting with your data fabric. It uses Appian AI Copilot to answer questions about records and related record data. By chatting with conversational AI, pharma industry users get quick insights that help them make better labeling decisions and stay compliant with regulations.
Records chat users’ access to record data is protected by role-based permissions.
The records chat component can be added to any screen in an Appian application to let users ask questions about their data
Appian generative AI extracts and summarizes key data points from internal and external sources like clinical trial documents and CCDS (Company Core Data Sheets), speeding up research for medical writers.
Appian generative AI can perform content comparisons. For example, it can analyze old and new labels or crosscheck new study findings against existing drug information. This ensures that critical updates, like the presence of a new ingredient, are quickly addressed across related labels.
Appian generative AI analyzes product data records to identify impacted drugs following signal detection
Appian AI can extract key data from unstructured labeling documents, such as CCDS documents or study findings. Appian transforms information into structured data that can be easily leveraged in downstream processes or displayed elsewhere in the application.
Appian generative AI analyzes and extracts data from CCDS documents, helping reviewers assess whether the new signal is partially or fully included
Appian generative AI enables dynamic translation management for multi-market labeling. AI automatically routes labels to specific workflows based on country and translates them accordingly. AI-generated translations are sent to human linguists for review, streamlining the process while ensuring compliance with country-specific regulations.
Appian generative AI translates multi-market labels and notifies reviewers to verify and refine the translated content
Appian AI continuously scans global regulatory updates and automatically flags any changes that might impact labels. It alerts regulatory teams of potential issues so they can act immediately.
Appian is now a Veeva AI partner, enabling seamless integration with Veeva RIM so organizations can leverage centralized regulatory data without complex migrations. This connectivity ensures accurate, up-to-date labeling information while streamlining compliance with global regulations.
AI has enormous potential to transform pharmaceutical labeling, but harnessing its full value relies on end-to-end process orchestration.
Appian is the leading platform for process orchestration, automation, and intelligence. We’ve been helping leading pharmaceutical companies transform their processes for over 25 years.
Are you ready for better labeling outcomes? Start unlocking efficient, accurate, and compliant labeling processes with Appian AI.